3-环戊氧基-4-甲氧基苯硼酸 | 159613-21-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 3-环戊氧基-4-甲氧基苯硼酸
• 英文名称: 3-cyclopentyloxy-4-methoxyphenylboronic acid
• 英文别名: (3-(Cyclopentyloxy)-4-methoxyphenyl)boronic acid；(3-cyclopentyloxy-4-methoxyphenyl)boronic acid
• CAS: 159613-21-5
• 化学式: C₁₂H₁₇BO₄
• mdl: MFCD04039013
• 分子量: 236.076
• InChiKey: PTXMXVNPZGJCAA-UHFFFAOYSA-N

物化性质

• 沸点：
  404.9±55.0 °C(Predicted)
• 密度：
  1.18±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.32
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  58.9
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 危险品标志：
  Xi
• 危险类别码：
  R36
• 危险性防范说明：
  P261,P264,P271,P280,P302+P352,P304+P340,P305+P351+P338,P312,P332+P313,P337+P313,P362,P403+P233,P405,P501
• 危险性描述：
  H315,H319,H335
• 储存条件：
  2-8°C，惰性气体

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 3-(Cyclopentyloxy)-4-methoxyphenylboronic acid
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 3-(Cyclopentyloxy)-4-methoxyphenylboronic acid
CAS number: 159613-21-5

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C12H17BO4
Molecular weight: 236.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-环戊氧基-4-甲氧基苯硼酸 在 氢氧化钾 、 sodium hydroxide 、 tetrafluoroboric acid 、 [Pd((S,S)-chiraphos)(PhCN)2](SbF₆)2 、 碘 、 sodium t-butanolate 、 lithium diisopropyl amide 作用下， 以 四氢呋喃 、 乙醇 、 二氯甲烷 、 水 、 二甲基亚砜 、 丙酮 为溶剂， 反应 44.83h， 生成 4-[(2R)-2-(3-环戊基氧基-4-甲氧基苯基)-2-苯基乙基]吡啶
  参考文献：
  名称：

  Palladium(II)-catalyzed 1,4-addition of arylboronic acids to β-arylenals for enantioselective syntheses of 3,3-diarylalkanals: a short synthesis of (+)-(R)-CDP 840

  摘要：

  1,4-Addition of arylboronic acid to trans-beta-arylenals proceeded smoothly in acetone-water (10/1) at 10-25 degrees C in the presence of [Pd(S,S-chirapbos)(PhCN)(2)](SbF6)(2) (0.5 mol %), AgX (X = BF4, SbF6, 10 mol %) and aqueous 42% HBF4 to afford optically active 3,3-diarylalkanals with high enantioselectivities in a range of 86-97% ee. The protocol provided a method for short-step synthesis of optically active (+)-(R)-CDP 840. (c) 2007 Published by Elsevier Ltd.

  DOI：

  10.1016/j.tetlet.2007.04.038
• 作为产物：
  描述：

  4-溴-2-(环戊基氧基)苯甲醚 在 1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物 sodium periodate 、 potassium acetate 作用下， 以 四氢呋喃 、 二甲基亚砜 为溶剂， 反应 37.0h， 生成 3-环戊氧基-4-甲氧基苯硼酸
  参考文献：
  名称：

  (-)-(R)-Rolipram、(-)-(R)-Baclofen 和其他 GABA 类似物通过芳基硼酸的铑催化共轭加成的对映选择性合成

  摘要：

  报道了两种重要的 γ-氨基丁酸 (GABA) 类似物，抗痉挛药物 (-)-(R)-巴氯芬和抗抑郁剂 (-)-(R)-Rolipram 的高度对映选择性合成。两种合成的关键步骤是芳基硼酸与 4-氨基丁-2,3-烯酸衍生物的 Rh 催化不对称 1,4-加成。

  DOI：

  10.1055/s-2003-42457

文献信息

• Aryl thiophene derivatives as PDE IV inhibitors
  申请人：Merck & Co., Inc.

  公开号：US06034089A1

  公开（公告）日：2000-03-07

  The invention encompasses the novel compound of Formula I useful in the treatment of diseases, including asthma, by raising the level of cyclic adenosine-3',5'-monophosphate (cAMP) through the inhibition of phosphodiesterase IV (PDE IV). ##STR1## The invention also encompasses certain pharmaceutical compositions and methods for treatment of diseases by inhibition of PDE IV, resulting in an elevation of cAMP, comprising the use of compounds of Formula I.

  该发明涵盖了一种新型化合物，其化学式为I，可用于治疗包括哮喘在内的疾病，通过通过抑制磷酸二酯酶IV（PDE IV）提高环状腺苷-3'，5'-单磷酸（cAMP）的水平。 该发明还涵盖了通过抑制PDE IV治疗疾病的某些药物组合物和方法，导致cAMP升高，包括使用化合物I的用途。
• General Access to <i>C</i>-Centered Radicals: Combining a Bioinspired Photocatalyst with Boronic Acids in Aqueous Media
  作者：Maheshwerreddy Chilamari、Jacob R. Immel、Steven Bloom

  DOI：10.1021/acscatal.0c03422

  日期：2020.11.6

  indispensable building blocks for modern synthetic chemistry. In recent years, visible light photoredox catalysis has become a promising avenue to access C-centered radicals from a broad array of latent functional groups, including boronic acids. Herein, we present an aqueous protocol wherein water features a starring role to help transform aliphatic, aromatic, and heteroaromatic boronic acids to C-centered

  以碳为中心的自由基是现代合成化学必不可少的组成部分。近年来，可见光光氧化还原催化已成为从包括硼酸在内的广泛的潜在官能团中进入以C为中心的自由基的有前途的途径。在本文中，我们介绍了一种水性方案，其中水起着星形作用，以帮助将脂族，芳族和杂芳族硼酸转化为C具有生物启发性的黄素光催化剂的中心自由基。这些自由基通过开壳共轭物加成到不同的Michael受体上，以递送各种不同的烷基化产物，包括三种药学上相关的化合物。通过计算研究，氘标记，自由基捕获实验和光谱分析研究了反应机理。
• Co-catalyzed reductive cyclization of azido and cyano substituted α,β-unsaturated esters with NaBH4: enantioselective synthesis of (R)-baclofen and (R)-rolipram
  作者：Abhimanyu S. Paraskar、Arumugam Sudalai

  DOI：10.1016/j.tet.2006.03.017

  日期：2006.5

  Sodium borohydride in combination with a catalytic amount of CoCl2 has been found to be an excellent catalytic system in reductive cyclizations of suitably substituted azido and cyano groups of α,β-unsaturated esters to afford γ and δ-lactams in high yields. The process has been demonstrated for the enantioselective synthesis of (R)-baclofen, (R)-rolipram, and (R)-4-fluorophenylpiperidinone, a key

  已经发现，将硼氢化钠与催化量的CoCl 2结合使用，是对α，β-不饱和酯的适当取代的叠氮基和氰基进行还原环化以提供高收率的γ和δ-内酰胺的优良催化体系。已经证明该方法可用于（R）-baclofen，（R）-咯利普兰和（R）-4-氟苯基哌啶酮（（-）-帕罗西汀的关键中间体）的对映选择性合成。
• Development and Analysis of a Pd(0)-Catalyzed Enantioselective 1,1-Diarylation of Acrylates Enabled by Chiral Anion Phase Transfer
  作者：Eiji Yamamoto、Margaret J. Hilton、Manuel Orlandi、Vaneet Saini、F. Dean Toste、Matthew S. Sigman

  DOI：10.1021/jacs.6b11367

  日期：2016.12.14

  Enantioselective 1,1-diarylation of terminal alkenes enabled by the combination of Pd catalysis with a chiral anion phase transfer (CAPT) strategy is reported herein. The reaction of substituted benzyl acrylates with aryldiazonium salts and arylboronic acids gave the corresponding 3,3-diarylpropanoates in moderate to good yields with high enantioselectivies (up to 98:2 er). Substituents on the benzyl

  本文报道了通过 Pd 催化与手性阴离子相转移 (CAPT) 策略相结合实现末端烯烃的对映选择性 1,1-二芳基化。取代的丙烯酸苄酯与芳基重氮盐和芳基硼酸反应，以中等至良好的产率和高对映选择性（高达 98:2 er）得到相应的 3,3-二芳基丙酸酯。丙烯酸苄酯和 CAPT 催化剂上的取代基显着影响对映选择性，多维参数化确定的相关性表明高立体控制的结构起源。
• Combining flavin photocatalysis with parallel synthesis: a general platform to optimize peptides with non-proteinogenic amino acids
  作者：Jacob R. Immel、Maheshwerreddy Chilamari、Steven Bloom

  DOI：10.1039/d1sc02562g

  日期：——

  even test up to 96 single-NPAA peptide variants via the unique combination of boronic acids and a dehydroalanine residue in a peptide. We showcase the power of our newly minted platform to introduce NPAAs of diverse chemotypes-aliphatic, aromatic, heteroaromatic-directly into peptides, including 15 entirely new residues, and to evolve a simple proteinogenic peptide into an unnatural inhibitor of thrombin

  大多数肽药物都含有非蛋白氨基酸 (NPAA)，这些氨基酸是通过使用固相肽合成 (SPPS) 进行的广泛构效关系 (SAR) 研究而产生的。 NPAA 的合成费力且制造成本昂贵，耦合效率也较差，只能通过传统 SPPS 采样一小部分。为了普遍获得含 NPAA 的肽，我们开发了第一代平台，将当代黄素光催化与平行合成相结合，通过硼酸的独特组合，同时制造、纯化、定量，甚至测试多达 96 种单 NPAA 肽变体。肽中的酸和脱氢丙氨酸残基。我们展示了我们新创建的平台的强大功能，可将不同化学类型（脂肪族、芳香族、杂芳香族）的 NPAA 直接引入肽中，包括 15 个全新残基，并通过非经典肽将简单的蛋白肽进化为非天然凝血酶抑制剂特别行政区。